Rachel L. Y. Wong,Megan R. E. Wong,Chik Hong Kuick,Seyed Ehsan Saffari,Meng Kang Wong,Sheng Hui Tan,Khurshid Merchant,Kenneth T. E. Chang,Matan Thangavelu,Giridharan Periyasamy,Zhi Xiong Chen,Prasad Iyer,Enrica E. K. Tan,Shui Yen Soh,N. Gopalakrishna Iyer,Qiao Fan,Amos H. P. Loh,Rachel L. Y. Wong,Megan R. E. Wong,Chik Hong Kuick,Seyed Ehsan Saffari,Meng Kang Wong,Sheng Hui Tan,Khurshid Merchant,Kenneth T. E. Chang,Matan Thangavelu,Giridharan Periyasamy,Zhi Xiong Chen,Prasad Iyer,Enrica E. K. Tan,Shui Yen Soh,N. Gopalakrishna Iyer,Qiao Fan,Amos H. P. Loh

Abstract:Neuroblastoma is the commonest extracranial pediatric malignancy. With few recurrent single nucleotide variations (SNVs), mutation-based precision oncology approaches have limited utility, but its frequent and heterogenous copy number variations (CNVs) could represent genomic dependencies that may be exploited for personalized therapy. Patient-derived cell culture (PDC) models can facilitate rapid testing of multiple agents to determine such individualized drug-responses. Thus, to study the relationship between individual genomic aberrations and therapeutic susceptibilities, we integrated comprehensive genomic profiling of neuroblastoma tumors with drug screening of corresponding PDCs against 418 targeted inhibitors. We quantified the strength of association between copy number and cytotoxicity, and validated significantly correlated gene-drug pairs in public data and using machine learning models. Somatic mutations were infrequent (3.1 per case), but copy number losses in 1p (31%) and 11q (38%), and gains in 17q (69%) were prevalent. Critically, in-vitro cytotoxicity significantly correlated only with CNVs, but not SNVs. Among 1278 significantly correlated gene-drug pairs, copy number of GNA13 and DNA damage response genes CBL, DNMT3A, and PPM1D were most significantly correlated with cytotoxicity; the drugs most commonly associated with these genes were PI3K/mTOR inhibitor PIK-75, and CDK inhibitors P276-00, SNS-032, AT7519, flavopiridol and dinaciclib. Predictive Markov random field models constructed from CNVs alone recapitulated the true z-score-weighted associations, with the strongest gene-drug functional interactions in subnetworks involving PI3K and JAK-STAT pathways. Together, our data defined individualized dose-dependent relationships between copy number gains of PI3K and STAT family genes particularly on 17q and susceptibility to PI3K and cell cycle agents in neuroblastoma. Integration of genomic profiling and drug screening of patient-derived models of neuroblastoma can quantitatively define copy number-dependent sensitivities to targeted inhibitors, which can guide personalized therapy for such mutationally quiet cancers.

Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

RNA-Sequencing Combined With Genome-Wide Allele-Specific Expression Patterning Identifies ZNF44 Variants as a Potential New Driver Gene for Pediatric Neuroblastoma

Pan-neuroblastoma Analysis Reveals Age- and Signature-Associated Driver Alterations.

Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients

Integrated Genomic Profiling and Drug Screening of Patient-Derived Cultures Identifies Individualized Copy Number-Dependent Susceptibilities Involving PI3K Pathway and 17q Genes in Neuroblastoma

Genomic Analysis-Integrated Whole-Exome Sequencing of Neuroblastomas Identifies Genetic Mutations in Axon Guidance Pathway

RNA-Seq Reveals Allele-Specific Expression of Somatic Mutations in Neuroblastoma

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma

Exploration of the molecular mechanism of intercellular communication in paediatric neuroblastoma by single-cell sequencing

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

Clinical Evaluation of Integrated Panel Testing by Next-Generation Sequencing for Somatic Mutations in Neuroblastomas with Mycn Unamplification

CRISPR-Cas9 Screening Develops an Epigenetic and Transcriptional Gene Signature for Risk Stratification and Target Prediction in Neuroblastoma

A Potential Prognostic Gene Signature Associated with p53-Dependent NTRK1 Activation and Increased Survival of Neuroblastoma Patients

Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease

BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study

Pathogenesis, Biomarkers and Therapeutic Targets

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy

Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma.